Provided by Tiger Trade Technology Pte. Ltd.

Cue Biopharma, Inc.

0.3100
-0.0101-3.16%
Volume:93.75K
Turnover:29.94K
Market Cap:28.28M
PE:-0.71
High:0.3300
Open:0.3180
Low:0.3050
Close:0.3201
52wk High:1.54
52wk Low:0.2302
Shares:91.24M
Float Shares:90.97M
Volume Ratio:0.46
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4366
EPS(LYR):-0.7221
ROE:-195.19%
ROA:-62.31%
PB:2.14
PE(LYR):-0.43

Loading ...

Cue Biopharma’s CUE-101 Trial Hits Completion: What It Means for Cancer Investors

TIPRANKS
·
Jan 23

Director Pasha Sarraf Reports Acquisition of Cue Biopharma Inc. Common Shares

Reuters
·
Jan 03

BRIEF-Cue Biopharma Announces Pricing Of $10 Million Public Offering

Reuters
·
Dec 19, 2025

Cue Biopharma Inc - Shares and Warrants Sold at Combined Price of $0.28

THOMSON REUTERS
·
Dec 19, 2025

Press Release: Cue Biopharma Announces Proposed Public Offering

Dow Jones
·
Dec 19, 2025

Cue Biopharma Chief Medical Officer Matteo Levisetti to Depart

Reuters
·
Nov 21, 2025

Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Reuters
·
Nov 20, 2025

BRIEF-Immunoscape Signs Deal With Cue Biopharma To Develop Solid Tumor Cancer Treatment

Reuters
·
Nov 14, 2025

Immunoscape: Entered in-Licensing Deal With Cue Biopharma for Development of New Class of Therapies to Attack Solid Tumor Cancers

THOMSON REUTERS
·
Nov 14, 2025

Cue Biopharma Licenses Immuno-STAT® Oncology Technology to ImmunoScape

Reuters
·
Nov 14, 2025

Cue Biopharma Q3 collaboration revenue falls

Reuters
·
Nov 13, 2025

Cue Biopharma Q3 EPS $(0.07) Beats $(0.09) Estimate, Sales $2.149M Miss $2.290M Estimate

Benzinga
·
Nov 13, 2025

Cue Biopharma Names Usman Azam President and CEO

Reuters
·
Nov 13, 2025

Cue Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights

THOMSON REUTERS
·
Nov 13, 2025

BRIEF-Cue Biopharma and ImmunoScape Announce Strategic Collaboration to Develop Breakthrough Cell Therapy Approach for Solid Tumors

Reuters
·
Nov 06, 2025

Cue Biopharma Inc. Files Initial Statement of Beneficial Ownership for CEO and Director Usman Azam

Reuters
·
Oct 03, 2025

BRIEF-Cue Biopharma Appoints New CEO, Shifts Focus to Autoimmune Therapies

Reuters
·
Sep 29, 2025

Cue Biopharma Appoints Usman Azam as CEO, Shifts Focus to Autoimmune Therapies as Daniel Passeri Becomes Strategic Advisor

Reuters
·
Sep 29, 2025

Cue Biopharma Announces Strategic Transition in Leadership to Further Enable Next Stage of Growth With Disruptive Autoimmune Therapeutic Candidates

THOMSON REUTERS
·
Sep 29, 2025

Cue Biopharma Inc - Usman Azam Appointed CEO of Cue Biopharma

THOMSON REUTERS
·
Sep 29, 2025